You are here
Home > Dilution > Mesna (Mesnex ®)

Mesna (Mesnex ®)

The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.    PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Usual Diluents

D5W, NS

Standard Dilutions   [Amount of drug] [Infusion volume] [Infusion rate]

[Usual dose] [100 ml] [15-30min]
(Concentration range: 1-20 mg/ml)

Stability / Miscellaneous

Dosing: usual dose=20% of ifosfamide dose given just before and 4 and 8 hours after ifosfamide (total=60%).
May also be given as a continuous IV infusion concurrently with ifosfamide. Total daily dose= 60% to 160% of ifosfamide dose or 60% to 200% of cyclophosphamide dose. May give 20% W/W 15min prior, and then q3hrs x 3-6 doses.

Administration: IVPB in 50 ml or more of D5W or normal saline over 5 minutes or longer. Also by continuous IV infusion.

Storage/stability: Vials stored at RT. Diluted solutions (1-20 mg/ml)-24 hrs (REF). 20 mg/ml (D5W)-48hrs RT; 1-mg/ml (D5W)-24 hours RT.

Preparation: May be further diluted in D5W, NS, D5/.45NS, or LR to a final concentration of 1-20 mg/ml.

DOSAGE AND ADMINISTRATION
For the prophylaxis of ifosfamide induced hemorrhagic cystitis, mesna may be given on a fractionated dosing schedule of three bolus intravenous injections as outlined below.

Intravenous Schedule
Mesna is given as intravenous bolus injections in a dosage equal to 20% of the ifosfamide dosage (w/w) at the time of ifosfamide administration and 4 and 8 hours after each dose of ifosfamide. The total daily dose of mesna is 60% of the ifosfamide dose.

The recommended dosing schedule is outlined below:

  0 Hours 4 Hours 8 Hours
Ifosfamide 1.2 g/m2
Mesna 240 mg/m2 240 mg/m2 240 mg/m2

Preparation of Intravenous Solutions/Stability
The mesna multidose vials may be stored and used for up to 8 days.
For IV administration the drug can be diluted by adding the Mesna Injection solution to any of the following fluids obtaining final concentrations of 20 mg mesna/mL.

*5% Dextrose Injection, USP
*5% Dextrose and 0.2% Sodium Chloride Injection, USP
*5% Dextrose and 0.33% Sodium Chloride Injection, USP
*5% Dextrose and 0.45% Sodium Chloride Injection, USP
*0.92% Sodium Chloride Injection, USP
*Lactated Ringer's Injection, USP

For example:
One mL of Mesna Injection multidose vial 100 mg/mL may be added to 4 mL of any of the solutions listed above to create a final concentration of 20 mg mesna/mL.

Diluted solutions are chemically and physically stable for 24 hours at 25°C (77°F).

Mesna is not compatible with cisplatin or carboplatin.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

HOW SUPPLIED
Mesna Injection is available as follows:
NDC 55390-266-01 1 gram; 10 mL Multidose Vial, individually boxed.
Store at 20° to 25°C (68° to 77°F). See USP for controlled room temperature.

Manufactured by: Manufactured for:
Ben Venue Laboratories, Inc. Amerinet Choice®
Bedford, OH 44146 St. Louis, MO 63146
July 2005 ANMSN-P00

Source: [package insert]

Disclaimer

The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user’s use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer